Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845912 | 1.00 | MAPK14 (0.68) | MAPK14MAPK10 | |
| SCHEMBL2843806 | 0.99 | MAPK14 (0.67) | MAPK14MAPK10 | |
| SCHEMBL5315388 | 0.96 | MAPK14 (0.64) | MAPK14MAPK10 | |
| SCHEMBL2842835 | 0.95 | MAPK14 (0.75) | MAPK14MAPK10 | |
| SCHEMBL2841223 | 0.95 | MAPK14 (0.75) | MAPK14MAPK10 | |
| SCHEMBL2840659 | 0.94 | MAPK14 (0.73) | MAPK14MAPK10 | |
| SCHEMBL5316005 | 0.93 | MAPK14 (0.68) | MAPK14MAPK10 | |
| SCHEMBL5310521 | 0.93 | MAPK14 (0.64) | MAPK14MAPK10 | |
| SCHEMBL2846010 | 0.90 | MAPK14 (0.59) | MAPK14MAPK10 | |
| SCHEMBL2843804 | 0.90 | MAPK14 (0.59) | MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | claimed |
| EP-1853581-B1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-06-02 | — | — | EP | claimed |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | MAPK14 1604/4885MAPK10 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.